Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases.

Anthos Therapeutics

VIRTRIS is a health data pioneer based in Seoul, South Korea, specializing in health data integration and analysis with the goal to accelerate drug discovery and approval.

VIRTRIS

Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases.Anthos Therapeutics aims to combine the agility of a biotech with the rigor of a large pharmaceutical company. Anthos Therapeutics was launched by Blackstone Life Sciences in 2019. 

Novo Seeds

Anthos Therapeutics’ CEO John Glasspool joined host Karen Jagoda on the #EmpoweredPatient Podcast. They discuss the bleeding risk associated with current #anticoagulants, and the potential benefits that a #hemostasis sparing #anticoagulant could offer patients. 

Listen: https://bit.ly/3L7FDfO

#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

Anthos Therapeutics’ CEO John Glasspool spoke with Daniel Levine about the development of #abelacimab, and the potential to uncouple the pathways for #thrombosis and #hemostasis by targeting #FactorXI.

Listen on #TheBioReport Podcast: https://bit.ly/3KRZxuR

#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

Anthos Therapeutics’ CMO Dan Bloomfield, MD, FACC, FAHA recently joined NPR’s Tech Nation, hosted by Moira Gunn, to discuss the current unmet needs in #anticoagulation and #abelacimab’s ability to provide effective anticoagulation with the potential for a lower bleeding risk.

Listen: https://bit.ly/3JzrtlQ
 
#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

Despite being a leading cause of death and disability worldwide, many people are unaware of venous #thromboembolism (VTE) and its associated health risks.
 
Educate yourself and others about #VTE with resources from WorldThrombosisDay & the International Society on Thrombosis and Haemostasis (ISTH): https://bit.ly/33SFSrY
 
#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

Anthos Therapeutics is developing the novel dual activity agent #abelacimab to target both #FactorXI and #FactorXIa, with the potential to turn our vision of hemostasis sparing #anticoagulation into reality.

Learn more about the promise of #FactorXI inhibition: https://bit.ly/3pZXcph

#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

According to the Centers for Disease Control and Prevention, 10 to 30% of people will die within one month of being diagnosed with venous thromboembolism. Our goal is to improve patient outcomes by developing a novel #anticoagulant with the potential to provide hemostasis-sparing anticoagulation.

Learn more about #VTE: https://bit.ly/3tL5aUz

#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

#ICYMI – Anthos Therapeutics CEO John Glasspool joined host Matthew Pillar on the BioProcess Online #BusinessOfBiotech #Podcast to discuss the clinical development of abelacimab and the potential for pipeline expansion to other areas of unmet need.
 
Listen: https://lnkd.in/dWh96btM
 
#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

We are pleased to announce that CEO John Glasspool was appointed to the Biotechnology Innovation Organization Board of Directors. John’s vast biotech experience and passion for helping patients will support BIO’s mission to drive a biotech revolution through education, collaboration, and advocacy.
 
Learn more: https://lnkd.in/gE69pKG
 
#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

February is #AmericanHeartMonth, a time to focus on #cardiovascular health and educate others about the risks of #HeartDisease. Anthos Therapeutics is a clinical stage #biopharma company committed to improving outcomes for patients with cardiovascular and metabolic diseases.
 
Get involved: https://lnkd.in/eETWjdV
 
#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

Metric
Company Name	Anthos Therapeutics	VIRTRIS
Symbol
MSH ID	COM:ANTHOSTHERAPEUTICS	COM:VIRTRIS
Market	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biopharmaceutical	Biotechnology
Country	US	KR
Stage
Employee Count	11
Website	anthostherapeutics.com	virtris.com
LinkedIn	anthos-therapeutics	virtus
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	12.98
28-Day Growth Score	17.19
90-Day Growth Score	59.46
365-Day Growth Score	79.96

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ANTHOSTHERAPEUTICS

Anthos Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue